Rhythm's setmelanotide awaits Japan verdict after US and EU nods in hypothalamic obesity
Japan's PMDA is reviewing setmelanotide for acquired hypothalamic obesity after the same pivotal trial cleared the FDA and European Commission this year, with a decision expected in the second half of 2026.
Executive Summary
- Japan's regulator is weighing an approval for setmelanotide in acquired hypothalamic obesity built on the same pivotal evidence that already won clearance in two other major markets this year.
- The relevant question is not whether the drug works, but whether the same result and safety profile that satisfied US and European regulators carries through Japanese review, including a Japanese patient cohort within the pivotal study.
- No other targeted therapy has reached Phase 3 for this mechanism in this indication, so the readthrough of this decision lands mainly on Rhythm's own pipeline rather than on rival programs.
- The trial's operational history shows routine registry housekeeping, not distress, so the open variable is regulatory timing and label scope in Japan, not the underlying data.
The application
PMDA accepted and validated Rhythm's Japanese New Drug Application for setmelanotide in acquired hypothalamic obesity and is now reviewing it, the company said, with a decision anticipated in the second half of 2026 and, if positive, a commercial launch expected before year-end. The application follows positive data from the Japanese cohort of the underlying Phase 3 study, which the company disclosed alongside the JNDA acceptance. Japan's health ministry had already granted the drug orphan drug designation for this indication in March 2025, ahead of the JNDA filing. RhythmRhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 5, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The evidence behind it
The application rests on NCT05774756, a randomized, placebo-controlled Phase 3 trial of setmelanotide against placebo in 143 patients with acquired hypothalamic obesity across the United States, Germany, Japan, the United Kingdom, Canada and the Netherlands. The trial's primary endpoint was mean percent change in BMI from baseline after 52 weeks on therapy, measured in a modified intent-to-treat population, and results have posted on the registry. Setmelanotide's safety data in the trial recorded two deaths and 26 patients with serious adverse events among 94 treated patients, against zero deaths and three serious-adverse-event cases among 48 patients on placebo, with skin hyperpigmentation, nausea, vomiting and headache among the most frequently reported adverse events. NCT05774756A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756
Already cleared elsewhere
That same evidence package has already supported regulatory clearance outside Japan: the FDA approved setmelanotide (IMCIVREE) for acquired hypothalamic obesity on March 19, 2026, and the European Commission separately granted marketing authorization for the same indication, the company said in its first-quarter 2026 update. Rhythm reported more than 150 patient start forms in the first six weeks of the US launch and $60.1 million in first-quarter global IMCIVREE net product revenue, driven mainly by the drug's existing Bardet-Biedl syndrome indication. The PMDA decision is therefore a question of whether the same result and safety profile clears a third jurisdiction, not whether the mechanism works. RhythmRhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 5, 2026
The competitive field
Setmelanotide is the only Phase 3 asset targeting MC4R in acquired hypothalamic obesity, and the broader MC4R agonist field in obesity totals 14 trials across three sponsors with no sibling-target program in Phase 3 or later. Rhythm's own weekly injectable follow-on, RM-718, is in Phase 1/2 testing for the same indication, and a second setmelanotide successor, bivamelagon, is in Phase 2 for hypothalamic obesity, making Rhythm's own pipeline the nearest comparator to this decision rather than a rival's. Field activity in MC4R research has slowed, with nine recent trials against 31 older ones, a pattern consistent with a mechanism that has already reached its most advanced applications rather than one still expanding.
Trial housekeeping
The trial's registry history shows a primary completion date pulled forward by one month, from April 16, 2025 to March 18, 2025, and enrollment revised from 120 to 143 patients when results posted on May 29, 2026, an increase the operational model treats as within its normal range rather than a departure from plan. The trial has cycled through two status changes, from recruiting to enrolling by invitation in January 2024 and then to active, not recruiting in February 2025, consistent with a study that completed enrollment and moved toward results on a predictable path. NCT05774756A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.